CFO — Geoffrey Parker: The CFO is retiring with advance notice, which constitutes an orderly succession rather than a sudden loss of a senior executive.

Results of Operations and Financial Condition. On August 12, 2026, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1…

Other Events. On June 22, 2026, the Company filed a prospectus supplement (the "Prospectus Supplement") with the Securities and Exchange Commission relating to sales of shares of its common stock having an aggregate offering price of up to $135.0 million to be sold pursuant to a certain Sales Agreement, dated November 5, 2019, as amended on November 2, 2022 and November 2, 2023 (as amended, the "Sales Agreement"), by and between the Company and TD Securities (U.S.A.) LLC (f/k/a Cowen and Comp…

President and Chief Executive Officer — David Chang, M.D., Ph.D.: Dr. Zachary Roberts was appointed as the new President and Chief Executive Officer, succeeding Dr. David Chang.

Results of Operations and Financial Condition. On May 13, 2026, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2026 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 193…

Termination of a Material Definitive Agreement The information set forth in

Entry into a Material Definitive Agreement On May 12, 2026, Allogene Therapeutics, Inc. (“Allogene”) entered into (i) a Termination Agreement (the “Termination Agreement”) with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. (collectively, the “Overland Parties”) and (ii) a Second Amended and Restated Shareholders’ Agreement (the “Shareholders Agreement”) with Overland Therapeutics Inc. ("Overland") and HH BioPharma Holdings Ltd. Pursuant to the Termination Agreement, the p…

Other Events. On April 14, 2026, we entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 87,500,000 shares of our common stock, par value $0.001 per share. The price to the public in the offering is $2.00 per share. The gross proceeds to us from the of…

Other Events On April 13, 2026, Allogene Therapeutics, Inc. (“Allogene” or the “Company”) announced interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (“cema-cel”) in first-line (“1L”) consolidation for large B-cell lymphoma (“LBCL”). The ALPHA3 trial is the first randomized study in LBCL designed to assess whether minimal residual disease (“MRD”)-guided intervention with cema-cel before relapse can eliminate residual disease and potentially prevent…

Other Events. On April 13, 2026, Allogene Therapeutics, Inc. (the “Company”) announced the commencement of a proposed underwritten public offering of its common stock. In connection with the Company’s proposed public offering, the Company has suspended the offering of any shares of its common stock pursuant to the sales agreement prospectus, dated April 25, 2024, contained in the Company’s Registration Statement on Form S-3 (File No. 333-277951) filed with the Securities and Exchange Commissi…

Results of Operations and Financial Condition. On March 12, 2026 , Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exc…

Results of Operations and Financial Condition. On November 6, 2025, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2025 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Ac…

Other Events. On September 26, 2025 , Factor Bioscience Inc. (“Factor”) filed a complaint in the United States District Court for the District of Delaware against our gene-editing technology licensor, Cellectis S.A., and its affiliate Cellectis, Inc. (collectively, “Cellectis”), alleging that Cellectis’s TALEN-based gene-editing technology infringed three of Factor’s U.S. patents relating to gene-editing techniques. Among other things, Factor alleges that Cellectis copied Factor’s patented mR…

Results of Operations and Financial Condition. On August 13, 2025, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2025 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1…

Other Events. On August 1, 2025, Allogene Therapeutics, Inc. (the “Company”) announced that it has selected standard fludarabine and cyclophosphamide (“FC”) as the lymphodepletion regimen to be used in its ALPHA3 study evaluating cemacabtagene ansegedleucel (“cema-cel”) in first-line consolidation for large B-cell lymphoma (“LBCL”). This lymphodepletion regimen selection was made in conjunction with the ALPHA3 Data and Safety Monitoring Board (“DSMB”) and Steering Committee and following cons…

Results of Operations and Financial Condition. On May 13, 2025, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2025 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On March 13, 2025, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exch…

Entry into a Material Definitive Agreement. On February 19, 2025, Allogene Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Strategic Collaboration Agreement (the “Amended Agreement”) with Foresight Diagnostics, Inc. (“Foresight”), which amended and restated the parties’ Strategic Collaboration Agreement, dated January 3, 2024, as amended (the “Original Agreement”). Under the Amended Agreement, the parties have agreed to expand their collaboration to enable the developm…

null — Timothy Moore: Mr. Moore is leaving his employment with the company.

Results of Operations and Financial Condition. On November 7, 2024, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Ac…

Results of Operations and Financial Condition. On August 7, 2024, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 19…

principal accounting officer — Annie Yoshiyama: Ms. Yoshiyama was promoted to principal accounting officer within the company.

Entry into a Material Definitive Agreement On May 24, 2024, Allogene Therapeutics, Inc. (the “Company”), Overland Pharmaceuticals (CY) Inc. (“Overland”) and Allogene Overland Biopharm (CY) Limited (the “JV Company”) entered into a Share Exchange Agreement pursuant to which Overland’s cell therapy business merged into the JV Company (the “Organizational Restructuring”). As background, the JV Company was originally formed on December 14, 2020 by Overland and the Company. Upon formation of the J…

Other Events. On May 13, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into (i) an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC (the “Underwriter”) and (ii) a securities purchase agreement (the “Securities Purchase Agreement”) with certain of its directors and executive officers (as described further below), relating to the issuance and sale in a registered offering of an aggregate of 37,931,035 shares of the Company’s common stock, par value…

Results of Operations and Financial Condition. On May 13, 2024, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 193…